X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4715) 4715
Newsletter (35) 35
Newspaper Article (14) 14
Book Chapter (12) 12
Magazine Article (12) 12
Dissertation (9) 9
Book Review (4) 4
Reference (2) 2
Government Document (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3868) 3868
thalidomide - analogs & derivatives (2960) 2960
thalidomide (1991) 1991
thalidomide - therapeutic use (1937) 1937
male (1786) 1786
female (1638) 1638
oncology (1480) 1480
middle aged (1372) 1372
multiple myeloma - drug therapy (1372) 1372
hematology (1364) 1364
aged (1307) 1307
lenalidomide (1286) 1286
thalidomide - administration & dosage (1255) 1255
multiple myeloma (1091) 1091
treatment outcome (983) 983
thalidomide - adverse effects (940) 940
antineoplastic combined chemotherapy protocols - therapeutic use (926) 926
adult (917) 917
bortezomib (828) 828
antineoplastic agents - therapeutic use (763) 763
thalidomide - pharmacology (761) 761
animals (729) 729
therapy (642) 642
aged, 80 and over (569) 569
cancer (550) 550
care and treatment (511) 511
dexamethasone - administration & dosage (504) 504
pharmacology & pharmacy (492) 492
dexamethasone (476) 476
chemotherapy (460) 460
stem-cell transplantation (413) 413
survival (401) 401
multiple-myeloma (398) 398
drug therapy (390) 390
multiple myeloma - pathology (384) 384
angiogenesis inhibitors - therapeutic use (372) 372
antineoplastic combined chemotherapy protocols - adverse effects (370) 370
immunologic factors - therapeutic use (362) 362
medicine & public health (354) 354
research (353) 353
mice (349) 349
recurrence (332) 332
angiogenesis (327) 327
prognosis (305) 305
disease-free survival (299) 299
hematology, oncology and palliative medicine (294) 294
analysis (292) 292
antineoplastic agents - adverse effects (286) 286
clinical trials as topic (285) 285
plus dexamethasone (285) 285
multiple myeloma - mortality (282) 282
multiple myeloma - therapy (282) 282
myelodysplastic syndromes - drug therapy (276) 276
dose-response relationship, drug (269) 269
antineoplastic agents - pharmacology (268) 268
transplantation (268) 268
abridged index medicus (263) 263
angiogenesis inhibitors (261) 261
boronic acids - therapeutic use (249) 249
health aspects (249) 249
pyrazines - therapeutic use (249) 249
efficacy (246) 246
expression (240) 240
analogs (239) 239
antineoplastic combined chemotherapy protocols - administration & dosage (233) 233
necrosis-factor-alpha (228) 228
drug therapy, combination (224) 224
combination (223) 223
cell line, tumor (219) 219
remission induction (219) 219
cells (217) 217
immunosuppressive agents - therapeutic use (217) 217
dexamethasone - therapeutic use (216) 216
retrospective studies (215) 215
disease progression (213) 213
clinical trials (212) 212
antineoplastic agents - administration & dosage (211) 211
dermatology (209) 209
boronic acids - administration & dosage (205) 205
pyrazines - administration & dosage (204) 204
myelodysplastic syndromes (203) 203
apoptosis (202) 202
trial (202) 202
survival analysis (201) 201
pomalidomide (200) 200
drug administration schedule (198) 198
thalidomide analogs (197) 197
risk factors (195) 195
immunology (194) 194
multiple myeloma - diagnosis (190) 190
survival rate (189) 189
follow-up studies (187) 187
myelodysplastic syndromes - genetics (187) 187
tnf-alpha (185) 185
myeloma (182) 182
dosage and administration (179) 179
medicine, general & internal (178) 178
combined modality therapy (176) 176
rituximab (175) 175
chromosome deletion (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4607) 4607
Japanese (115) 115
German (43) 43
French (36) 36
Chinese (27) 27
Spanish (20) 20
Czech (18) 18
Portuguese (11) 11
Polish (5) 5
Danish (2) 2
Hungarian (2) 2
Italian (2) 2
Korean (1) 1
Russian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6414, pp. eaat0572 - 558
Journal Article
Nature structural & molecular biology, ISSN 1545-9985, 2014, Volume 21, Issue 9, pp. 803 - 809
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2019, Volume 20, Issue 3, p. 502
Journal Article
Clinical & Experimental Immunology, ISSN 0009-9104, 10/2002, Volume 130, Issue 1, pp. 75 - 84
.... More recently, Thd has also been shown to co‐stimulate T cells and second generation co‐stimulatory (IMiD™) analogues are currently being assessed in the treatment of cancer patients... 
immunomodulation | T lymphocyte | co‐stimulation | thalidomide | TNF | Co-stimulation | Immunomodulation | Thalidomide | MULTIPLE-MYELOMA | ACTIVATION | PHASE-II | IMMUNOLOGY | co-stimulation | POTENT INHIBITORS | CC-3052 | INHIBITORY ACTIVITY | IN-VITRO | THERAPY | IMMUNODEFICIENCY-VIRUS INFECTION | APHTHOUS ULCERS | Adjuvants, Immunologic - pharmacology | Antigens, CD - biosynthesis | Humans | Middle Aged | Tumor Necrosis Factor-alpha - genetics | Male | Thalidomide - pharmacology | Antigens, CD - genetics | Receptors, Interleukin-2 - genetics | Thalidomide - analogs & derivatives | Neoplasms - therapy | Neoplasms - blood | Receptors, Tumor Necrosis Factor - antagonists & inhibitors | Receptors, Tumor Necrosis Factor, Type II | CD8-Positive T-Lymphocytes - metabolism | Adult | Female | Adjuvants, Immunologic - therapeutic use | Receptors, Tumor Necrosis Factor - genetics | Cells, Cultured - drug effects | Enzyme-Linked Immunosorbent Assay | Lenalidomide | Receptors, Interleukin-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | CD4-Positive T-Lymphocytes - metabolism | Solubility | Phosphodiesterase Inhibitors - pharmacology | Inflammation | Antigens, CD - drug effects | Signal Transduction - drug effects | Lymphocyte Activation - drug effects | CD8-Positive T-Lymphocytes - drug effects | CD3 Complex - immunology | Lipopolysaccharides - pharmacology | Receptors, Tumor Necrosis Factor - biosynthesis | Aged | Cells, Cultured - metabolism | Thalidomide - therapeutic use | Tumor Necrosis Factor-alpha - biosynthesis | CD4-Positive T-Lymphocytes - drug effects | Receptors, Tumor Necrosis Factor - drug effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Basic Immunology
Journal Article
Chemical research in toxicology, ISSN 0893-228X, 01/2014, Volume 27, Issue 1, pp. 147 - 156
Journal Article
The AAPS journal, ISSN 1550-7416, 2005, Volume 7, Issue 1, pp. E14 - E19
Thalidomide and its immunomodulatory (IMiDs) analogs (lenalidomide, Revlimid, CC-5013... 
cytokine | Biotechnology | multiple myeloma | Pharmacy | lenalidomide | Pharmacology/Toxicology | Thalidomide | IMiDs | anti-cancer | immunomodulatory | Lenalidomide | Cytokine | Multiple myeloma | Anti-cancer | Immunomodulatory | PHASE-II | NECROSIS-FACTOR-ALPHA | DRUG-RESISTANCE | MULTIPLE-MYELOMA CELLS | POTENT INHIBITORS | CYTOKINE PRODUCTION | thalidomide | PHARMACOLOGY & PHARMACY | DERIVATIVES | LYMPHOCYTES | T-Lymphocyte Subsets - immunology | Apoptosis - drug effects | Humans | Endothelium, Vascular - drug effects | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Thalidomide - analogs & derivatives | Clinical Trials, Phase III as Topic | Multiple Myeloma - drug therapy | T-Lymphocyte Subsets - drug effects | Angiogenesis Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Interferon-gamma - secretion | Thalidomide - chemistry | Angiogenesis Inhibitors - pharmacology | Neoplasms - blood supply | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Endothelium, Vascular - metabolism | Lymphocyte Activation - drug effects | Neoplasms - immunology | Killer Cells, Natural - drug effects | Cytokines - antagonists & inhibitors | T-Lymphocyte Subsets - secretion | Thalidomide - therapeutic use | Interleukin-2 - secretion | Immunologic Factors - pharmacology | Clinical Trials, Phase II as Topic | Drug Screening Assays, Antitumor | Immunologic Factors - therapeutic use
Journal Article